Ligand Rises on FDA Blood Drug Approval for Hepatitis C
This article is for subscribers only.
Ligand Pharmaceuticals Inc. rose the most in 14 months after its drug to help people with low blood platelet counts was approved by U.S. regulators for use in hepatitis C patients.
Ligand rose 14 percent to $19.07 at the close in New York, its biggest one-day gain since August 2011. The La Jolla, California-based company said today the Food and Drug Administration approved the medicine to enable hepatitis C patients with low blood platelet counts to take interferon therapy.